Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
WCLC 2016 – Lung Cancer
First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC (CheckMate 012)
WCLC 2016 – Lung Cancer
Conference Correspondent
Nivolumab, a PD-1 immune checkpoint inhibitor, has demonstrated superior efficacy relative to docetaxel in patients with advanced non–small-cell lung cancer (NSCLC) who progressed on or after platinum-based chemotherapy regardless of PD-L1 expression. Researchers presented findings from a phase 1 study of nivolumab as first-line therapy for advanced NSCLC.
Read Article
Pembrolizumab in Patients with Extensive-Stage Small-Cell Lung Cancer (SCLC): KEYNOTE-028
WCLC 2016 – Lung Cancer
Conference Correspondent
Extensive-stage disease (ED) small-cell lung cancer (SCLC) is characterized by limited treatment options and poor survival after platinum-based chemotherapy. Pembrolizumab, an inhibitor of PD-1, is active and safe in multiple solid tumors. Researchers presented updated safety and efficacy data for patients with ED SCLC who enrolled in KEYNOTE-028.
Read Article
Atezolizumab as First-Line Therapy for Advanced NSCLC in PD-L1–Selected Patients (BIRCH)
WCLC 2016 – Lung Cancer
Conference Correspondent
Atezolizumab, a humanized anti–PD-L1 monoclonal antibody, is being assessed in a phase 2 study in PD-L1–selected advanced non–small-cell lung cancer (NSCLC) patients. Initial analysis demonstrated a meaningful objective response rate with durable response in chemotherapy-naive first-line and relapsed PD-L1–selected patients. Researchers reported updated efficacy data in these first-line patients.
Read Article
Cost-Effectiveness Comparison of Screening Options for Lung Cancer Based on Randomized Population Trials
WCLC 2016 – Lung Cancer
Conference Correspondent
Based on data from the National Lung Screening Trial comparing lung cancer mortality associated with computed tomography (CT) and chest x-ray screening, CT screening is now standard clinical practice. However, questions about the value of CT screening remain given its cost and risk of false-positive results.
Read Article
Noninvasive Testing for Early-Stage Lung Cancer Chemoprevention Therapy
WCLC 2016 – Lung Cancer
Conference Correspondent
Rates of early detection of lung cancer remain poor. Identification of endobronchial lung dysplasia with a noninvasive sputum-based test could facilitate chemoprevention. Researchers evaluated a novel test for early-stage lung cancer to determine if it can identify tumor cells that have been exfoliated into sputum.
Read Article
Randomized Phase 3 Study of Osimertinib vs Platinum-Pemetrexed for Patients with EGFR T790M-Positive Advanced NSCLC After EGFR-TKI Therapy (AURA3)
WCLC 2016 – Lung Cancer
Conference Correspondent
Osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is indicated for use in patients with locally advanced or metastatic EGFR
T790M
-positive non–small-cell lung cancer (NSCLC) who have progressed on or after EGFR-TKI therapy. Researchers compared the efficacy and safety of osimertinib with platinum-based chemotherapy plus pemetrexed in this patient population.
Read Article
Randomized, Phase 3 Study of First-Line Ceritinib vs Chemotherapy in Patients with ALK-Positive NSCLC (ASCEND-4)
WCLC 2016 – Lung Cancer
Conference Correspondent
Ceritinib is approved for use in patients with advanced
ALK
-positive non–small-cell lung cancer (NSCLC) who have progressed following treatment with crizotinib. In ASCEND-4, a multicenter randomized trial in previously untreated adult patients, researchers assessed progression-free survival outcomes for ceritinib compared with standard first-line and maintenance chemotherapy.
Read Article
Efficacy and Safety of Necitumumab plus Pembrolizumab in Patients Who Relapsed After Chemotherapy for Metastatic Nonsquamous NSCLC
WCLC 2016 – Lung Cancer
Conference Correspondent
Necitumumab, an epidermal growth factor receptor inhibitor, is approved with gemcitabine and cisplatin for previously untreated advanced squamous non–small-cell lung cancer (NSCLC). Nivolumab, a PD-1 inhibitor, is approved for previously untreated NSCLC, as well as relapsed NSCLC, based on PD-L1 expression. This phase 1b study evaluated combination use of these agents.
Read Article
Pembrolizumab + Carboplatin and Pemetrexed as First-Line Therapy for Advanced NSCLC (KEYNOTE-021 Cohort G)
WCLC 2016 – Lung Cancer
Conference Correspondent
Platinum-based chemotherapy with or without bevacizumab is standard first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) without genetic aberrations. Pembrolizumab has demonstrated activity in PD-L1–positive advanced NSCLC. Cohort G of the phase 1/2 KEYNOTE-021 study compared pembrolizumab + carboplatin and pemetrexed (CP) with CP in patients with treatment-naive advanced nonsquamous NSCLC.
Read Article
Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation and PD-L1–Positive Metastatic NSCLC
WCLC 2016 – Lung Cancer
Conference Correspondent
Abemaciclib, a small-molecule inhibitor of both cyclin-dependent kinase (CDK)4 and CDK6, has demonstrated single-agent activity in patients with solid tumors, including non–small-cell lung cancer (NSCLC). Pembrolizumab, an inhibitor of PD-1, is approved for patients with metastatic PD-L1–positive NSCLC. Researchers studied abemaciclib combined with pembrolizumab in pretreated patients with NSCLC.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma